117 related articles for article (PubMed ID: 29095648)
1. Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study.
Kawaguchi H; Masuda N; Nakayama T; Aogi K; Anan K; Ito Y; Ohtani S; Sato N; Saji S; Takano T; Tokunaga E; Nakamura S; Hasegawa Y; Hattori M; Fujisawa T; Morita S; Yamaguchi M; Yamashita H; Yamashita T; Yamamoto Y; Yotsumoto D; Toi M; Ohno S
Curr Med Res Opin; 2018 Jan; 34(1):49-54. PubMed ID: 29095648
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari).
Kawaguchi H; Masuda N; Nakayama T; Aogi K; Anan K; Ito Y; Ohtani S; Sato N; Saji S; Tokunaga E; Nakamura S; Hasegawa Y; Hattori M; Fujisawa T; Morita S; Yamaguchi M; Yamashita T; Yamamoto Y; Ohno S; Toi M
Breast Cancer Res Treat; 2017 Jun; 163(3):545-554. PubMed ID: 28337663
[TBL] [Abstract][Full Text] [Related]
3. Fulvestrant with or without anti-HER2 therapy in patients in a postmenopausal hormonal state and with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG-C06).
Masuyama M; Masuda N; Kawaguchi H; Yamamoto Y; Saji S; Nakayama T; Aogi K; Anan K; Ohtani S; Sato N; Takano T; Tokunaga E; Nakamura S; Hasegawa Y; Hattori M; Fujisawa T; Morita S; Yamaguchi M; Yamashita T; Yotsumoto D; Toi M; Ohno S
Cancer Med; 2023 Sep; 12(17):17718-17730. PubMed ID: 37525895
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study.
Kawaguchi H; Masuda N; Nakayama T; Aogi K; Anan K; Ito Y; Ohtani S; Sato N; Saji S; Takano T; Tokunaga E; Nakamura S; Hasegawa Y; Hattori M; Fujisawa T; Morita S; Yamaguchi M; Yamashita H; Yamashita T; Yamamoto Y; Yotsumoto D; Toi M; Ohno S
Breast Cancer; 2020 May; 27(3):389-398. PubMed ID: 31811519
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of fulvestrant 500 mg in Japanese postmenopausal advanced/recurrent breast cancer patients and factors associated with prolonged time-to-treatment failure.
Araki K; Ishida N; Horii R; Takahashi S; Akiyama F; Ito Y; Ohno S
Expert Opin Pharmacother; 2015; 16(17):2561-8. PubMed ID: 26558799
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study.
Kawaguchi H; Yamamoto Y; Saji S; Masuda N; Nakayama T; Aogi K; Anan K; Ito Y; Ohtani S; Sato N; Takano T; Tokunaga E; Nakamura S; Hasegawa Y; Hattori M; Fujisawa T; Morita S; Yamaguchi M; Yamashita H; Yamashita T; Yotsumoto D; Toi M; Ohno S
Jpn J Clin Oncol; 2022 May; 52(6):545-553. PubMed ID: 35296894
[TBL] [Abstract][Full Text] [Related]
7. Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study.
Kawaguchi H; Yamamoto Y; Saji S; Masuda N; Nakayama T; Aogi K; Anan K; Ohtani S; Sato N; Takano T; Tokunaga E; Nakamura S; Hasegawa Y; Hattori M; Fujisawa T; Morita S; Yamaguchi M; Yamashita T; Yotsumoto D; Toi M; Ohno S
Jpn J Clin Oncol; 2023 Mar; 53(3):203-211. PubMed ID: 36484305
[TBL] [Abstract][Full Text] [Related]
8. Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre.
Catania C; Ascione G; Adamoli L; De Pas T; Medici M; Franceschelli L; Verri E; Magni E; Sanna G; Torrisi R; Goldhirsch A; Nolè F
Breast Cancer Res Treat; 2007 Nov; 106(1):97-103. PubMed ID: 17260095
[TBL] [Abstract][Full Text] [Related]
9. Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experience.
Steger GG; Bartsch R; Wenzel C; Pluschnig U; Hussian D; Sevelda U; Locker GJ; Gnant MF; Jakesz R; Zielinski CC
Eur J Cancer; 2005 Nov; 41(17):2655-61. PubMed ID: 16230005
[TBL] [Abstract][Full Text] [Related]
10. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
Mlineritsch B; Psenak O; Mayer P; Moik M; Namberger K; Hauser-Kronberger C; Greil R
Breast Cancer Res Treat; 2007 Nov; 106(1):105-12. PubMed ID: 17295045
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice.
Blancas I; Fontanillas M; Conde V; Lao J; Martínez E; Sotelo MJ; Jaen A; Bayo JL; Carabantes F; Illarramendi JJ; Gordon MM; Cruz J; García-Palomo A; Mendiola C; Pérez-Ruiz E; Bofill JS; Baena-Cañada JM; Jáñez NM; Esquerdo G; Ruiz-Borrego M
Clin Transl Oncol; 2018 Jul; 20(7):862-869. PubMed ID: 29178019
[TBL] [Abstract][Full Text] [Related]
12. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
Robertson JF; Osborne CK; Howell A; Jones SE; Mauriac L; Ellis M; Kleeberg UR; Come SE; Vergote I; Gertler S; Buzdar A; Webster A; Morris C
Cancer; 2003 Jul; 98(2):229-38. PubMed ID: 12872340
[TBL] [Abstract][Full Text] [Related]
13. Patient database analysis of fulvestrant 500 mg in the treatment of metastatic breast cancer: A European perspective.
Marchetti P; Maass N; Gligorov J; Berger K; MacDougall F; Montonen J; Lewis J
Breast; 2017 Apr; 32():247-255. PubMed ID: 28011074
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis.
Wang J; Xu B; Wang W; Zhai X; Chen X
Breast Cancer Res Treat; 2018 Oct; 171(3):535-544. PubMed ID: 29974356
[TBL] [Abstract][Full Text] [Related]
15. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Robertson JFR; Bondarenko IM; Trishkina E; Dvorkin M; Panasci L; Manikhas A; Shparyk Y; Cardona-Huerta S; Cheung KL; Philco-Salas MJ; Ruiz-Borrego M; Shao Z; Noguchi S; Rowbottom J; Stuart M; Grinsted LM; Fazal M; Ellis MJ
Lancet; 2016 Dec; 388(10063):2997-3005. PubMed ID: 27908454
[TBL] [Abstract][Full Text] [Related]
16. Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy.
Telford C; Jones N; Livings C; Batson S
Clin Breast Cancer; 2016 Jun; 16(3):188-95. PubMed ID: 26971303
[TBL] [Abstract][Full Text] [Related]
17. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
[TBL] [Abstract][Full Text] [Related]
18. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
McKeage K; Curran MP; Plosker GL
Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
[TBL] [Abstract][Full Text] [Related]
19. Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies.
Agrawal A; Robertson JF; Cheung KL; Gutteridge E; Ellis IO; Nicholson RI; Gee JM
Int J Cancer; 2016 Jan; 138(1):146-59. PubMed ID: 26178788
[TBL] [Abstract][Full Text] [Related]
20. [Experience of Fulvestrant for Hormone Receptor-Positive HER2-Negative Advanced and Metastatic Breast Cancer].
Soshi M; Kawasaki S; Kawamura Y; Watanebe A; Iguchi E; Nishida M; Sakuramachi A; Morita M; Oouchi Y; Nakatsukasa K; Sakaguchi K; Taguchi T
Gan To Kagaku Ryoho; 2018 Jun; 45(6):949-954. PubMed ID: 30026420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
